Michael Chambers - 19 Aug 2022 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role: Director
Signature: /s/ Ryan Brown, as Attorney-in-Fact for Michael Andrew Chambers
Issuer symbol: SRPT
Transactions as of: 19 Aug 2022
Transactions value $: $4,999,230
Form type: 4
Filing time: 22 Aug 2022, 08:30:47
Previous filing: 06 Jun 2022
Next filing: 14 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRPT	Common Stock	Purchase	$4.34M	+40.1K	+817.24%	$108.20	45K	19 Aug 2022	Direct	F1
transaction	SRPT	Common Stock	Purchase	$659K	+6.06K	+13.46%	$108.80	51.1K	19 Aug 2022	Direct	F2
holding	SRPT	Common Stock						75.2K	19 Aug 2022	By Revocable Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.56 to $108.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.57 to $109.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $107.56 to $108.56, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.57 to $109.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.